Lawmakers Parrot Drug Makers’ Arguments For Wider CAR-T Coverage

By John Wilkerson / May 8, 2019 at 5:00 PM
As the May 17 final coverage decision looms, bipartisan groups of Senate and House lawmakers are taking the side of drug makers that want Medicare to cover expensive CAR-T cancer therapies for more patients and in more settings. The lawmakers ask that CMS let doctors administer chimeric antigen receptor (CAR) T-cells therapy outside of hospitals, pay for off-label indications, avoid disrupting care of patients already receiving CAR-T and avoid excluding coverage of future cell and gene therapy therapies. CMS is...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.